|
Adult T-Cell Lymphoma/Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Integrated molecular analysis of adult T cell leukemia/lymphoma.
|
26437031 |
2015 |
|
Anhedonia
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Effects of chemokine receptor signalling on cognition-like, emotion-like and sociability behaviours of CCR6 and CCR7 knockout mice.
|
24333375 |
2014 |
|
Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The demonstration of the progressive changes of CCR7-10 during and after status epilepticus may open a new area to reveal the mechanism of neuronal loss after status epilepticus and of epileptogenesis.
|
17181556 |
2007 |
|
Petit mal status
|
0.300 |
Biomarker
|
disease |
CTD_human |
CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.
|
17181556 |
2007 |
|
Grand Mal Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.
|
17181556 |
2007 |
|
Complex Partial Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.
|
17181556 |
2007 |
|
Status Epilepticus, Subclinical
|
0.300 |
Biomarker
|
disease |
CTD_human |
CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.
|
17181556 |
2007 |
|
Non-Convulsive Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.
|
17181556 |
2007 |
|
Simple Partial Status Epilepticus
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
CCR7, CCR8, CCR9 and CCR10 in the mouse hippocampal CA1 area and the dentate gyrus during and after pilocarpine-induced status epilepticus.
|
17181556 |
2007 |
|
Sjogren's Syndrome
|
0.220 |
Biomarker
|
disease |
BEFREE |
Additional immunofluorescence studies demonstrated high expression and co-localisation of CCL21 chemokine and CCR7 chemokine receptor within the SS infiltrates.
|
28421997 |
2017 |
|
Sjogren's Syndrome
|
0.220 |
Biomarker
|
disease |
MGD |
NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells.
|
22538615 |
2012 |
|
Sjogren's Syndrome
|
0.220 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that variants of CCR7 gene occur at an extremely low frequency in the German population and that neither Sjogren's syndrome, systemic lupus erythematosus, nor systemic sclerosis are associated with these variants.
|
17587445 |
2007 |
|
Sjogren's Syndrome
|
0.220 |
Biomarker
|
disease |
MGD |
CCR7-dependent cortex-to-medulla migration of positively selected thymocytes is essential for establishing central tolerance.
|
16473829 |
2006 |
|
Sjogren's Syndrome
|
0.220 |
Biomarker
|
disease |
MGD |
CCR7 signals are essential for cortex-medulla migration of developing thymocytes.
|
15302902 |
2004 |
|
Sicca Syndrome
|
0.200 |
Biomarker
|
disease |
MGD |
NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells.
|
22538615 |
2012 |
|
Sicca Syndrome
|
0.200 |
Biomarker
|
disease |
MGD |
CCR7-dependent cortex-to-medulla migration of positively selected thymocytes is essential for establishing central tolerance.
|
16473829 |
2006 |
|
Sicca Syndrome
|
0.200 |
Biomarker
|
disease |
MGD |
CCR7 signals are essential for cortex-medulla migration of developing thymocytes.
|
15302902 |
2004 |
|
Leukemogenesis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, reduced GATA2 expression suppresses the differentiation but promotes the proliferation of EVI1-expressing leukemic cells, which accelerates EVI1-driven leukemogenesis.
|
31820561 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CCL19, a ligand of CCR7, could promote trophoblast migration and invasion by activating the deregulation of the CCR7-mediated pathway in RSA.
|
31504210 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results revealed that EVI‑1 may be a potential effective therapeutic target in breast cancer.
|
30592274 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of Ets-1 increased CCR7 expression in breast cancer cell lines.
|
31072446 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data show significant correlations between (i) higher frequencies of CD8<sup>+</sup> naïve (P = 0.02) and effector memory (P = 0.003) T cells and lower frequencies of CD8<sup>+</sup> central memory T cells (P = 0.002) with stronger handgrip strength, (ii) lower frequency of regulatory cells with greater lean mass index (P = 0.04), (iii) lower frequency of CD8<sup>+</sup> T cells that express CD95 with greater stair climb power (P = 0.003), (iv) higher frequency of T cells that co-express CD197 and CD45RA and greater one-repetition maximum knee extension strength (P = 0.008), and (iv) higher expression of CD4 in whole blood with greater functional impairment (P = 0.004) in people with cancer.
|
30977974 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analysis of melanoma-derived cancer stem cells (CSC) showed high CCR7 expression; these CSCs were efficiently recognized and killed by NK cells.
|
30940644 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
β-catenin mediated EVI1's function on cancer stem cells (CSCs) properties.
|
30770775 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Aberrant EVI‑1 expression has been reported to be a characteristic of multiple types of malignancies; however, very little is known about how EVI‑1 regulates breast cancer.
|
30592274 |
2019 |